Sulfonamides and Cotrimoxazole: Folate Inhibition, Clinical Uses and Monitoring

Educational review updated 10 November 2026. Antimicrobial selection and dosing must reflect patient factors, susceptibility data and current local guidance.

Overview

Antibacterial sulfonamides were among the earliest effective systemic antibiotics. Cotrimoxazole combines sulfamethoxazole (SMX), a sulfonamide, with trimethoprim (TMP), a diaminopyrimidine, not a second sulfonamide. Their sequential blockade of folate synthesis provides activity against selected bacteria and Pneumocystis jirovecii [1–3].

Mechanism and classification

SMX competes with para-aminobenzoic acid at bacterial dihydropteroate synthase. TMP inhibits bacterial dihydrofolate reductase, reducing tetrahydrofolate and nucleotide synthesis. Combined effects can be synergistic and bactericidal for susceptible bacteria, but activity depends on organism and resistance. Sulfadiazine is used with pyrimethamine in selected toxoplasmosis regimens; topical sulfacetamide and silver sulfadiazine have distinct roles [1].

Clinical uses

TMP-SMX is used for susceptible urinary tract infections, selected skin infections including some community-associated MRSA infections, Nocardia disease and some Stenotrophomonas maltophilia infections depending on resistance and alternative agents [1,2]. It is the preferred agent for prophylaxis and treatment of Pneumocystis pneumonia (PCP) in people with HIV. For established HIV-associated PCP, the guideline-recommended treatment course is generally 21 days; moderate/severe disease may require intravenous treatment and adjunctive corticosteroids based on oxygenation criteria [3].

Pharmacokinetics

TMP and SMX are well absorbed orally, distribute into many tissues and undergo predominantly renal clearance of drug and metabolites. Dosing varies widely by syndrome (routine cystitis versus high-dose PCP); check kidney function and adjust when necessary. TMP can raise serum creatinine by inhibiting tubular secretion without a corresponding fall in measured GFR, but true AKI can also occur [1].

Adverse effects

Rash, nausea and gastrointestinal upset are common. Serious reactions include Stevens–Johnson syndrome/toxic epidermal necrolysis, DRESS, cytopenias, hepatitis, kidney injury and hyperkalemia; TMP causes potassium retention through amiloride-like effects in the distal nephron. SMX can precipitate hemolysis in susceptible G6PD-deficient patients. Monitor complete blood count, potassium and kidney function when clinically indicated, especially with high doses or prolonged therapy [1,3].

Interactions and pregnancy

TMP-SMX can potentiate warfarin, and hyperkalemia risk rises with ACE inhibitors, ARBs or spironolactone. It may increase methotrexate toxicity and should generally not be combined casually with methotrexate. TMP inhibits folate metabolism; early pregnancy considerations require weighing indication, alternative agents and folate supplementation with specialist advice. Avoid outdated categorical statements that TMP-SMX is universally forbidden in pregnancy: life-threatening PCP can require it [3].

Resistance and stewardship

Resistance arises via altered folate-synthesis enzymes, bypass pathways or reduced uptake. Use local susceptibilities, infection-specific guidance and adequate monitoring; do not assume all sulfonamides have interchangeable antibacterial activity [1,2].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. Infectious Diseases Society of America. IDSA 2026 guidance on antimicrobial resistant Gram-negative infections. 2026 Jul 30. Available from: https://www.idsociety.org/practice-guideline/amr-guidance/
  3. National Institutes of Health. Pneumocystis pneumonia: adult and adolescent opportunistic infections guidelines. Updated 2026. Available from: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/pneumocystis
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *